AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2021
Jul 9, 2021
35172_dirs_2021-07-09_307f1e33-a3bd-489f-9b11-a44573fe499b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-07-08
Reporting Person: Guy Wendy (Chief Administrative Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-08 | Restricted Stock Units | $0 | A | 8572 | Acquired | Common Stock (8572) | Direct | |
| 2021-07-08 | Restricted Stock Units | $0 | A | 12858 | Acquired | Common Stock (12858) | Direct | |
| 2021-07-08 | Restricted Stock Units | $0 | A | 1907 | Acquired | Common Stock (10034) | Direct |
Footnotes
F1: The restricted stock units vest in two equal installments beginning July 1, 2022.
F2: The Restricted Stock Units vest upon achievement of certain performance goals.
F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15